Orphan Drugs for Cancer Pipeline Analysis

Publish Date:- Oct-2013       No Of Pages (855)

Electronic Access - Single User License $1800 Buy Now
CD-ROM Mail Delivery $2400Buy Now
Hard Copy Mail Delivery $3000 Buy Now
Electronic Access - Multi-User License $3600 Buy Now


A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed for treating rare cancer diseases like solid tumor of the pancreas and thyroid, blood cancer, melanoma, and others.

Orphan Drugs for Cancer Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed for the treatment of multiple cancers. Research report covers all the ongoing vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the market for orphan designated cancer drugs based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Detailed Therapeutic Trials

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Orphan Designated Drugs for Cancer Treatment by Clinical Development Phase:

• Preclinical: 11

• Phase-I: 25

• Phase-I/II: 33

• Phase-II: 68

• Phase-II/III: 6

• Phase-III: 41

• Preregistration: 8

• Registered: 3

• Marketed: 59


A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed for treating rare cancer diseases like solid tumor of the pancreas and thyroid, blood cancer, melanoma, and others.

Orphan Drugs for Cancer Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various orphan designated drugs being developed for the treatment of multiple cancers. Research report covers all the ongoing vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the market for orphan designated cancer drugs based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in “Orphan Drugs for Cancer Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Detailed Therapeutic Trials

• Mechanism of Action

• Brand Name

• Patent Information

• Orphan Designation by Indication, Country & Organisation

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Orphan Designated Drugs for Cancer Treatment by Clinical Development Phase:

• Preclinical: 11

• Phase-I: 25

• Phase-I/II: 33

• Phase-II: 68

• Phase-II/III: 6

• Phase-III: 41

• Preregistration: 8

• Registered: 3

• Marketed: 59

1. Orphan Drug for Cancer Market Overview



2. Clinical Phase for Orphan Designated Cancer Drug: Preclinical

  2.1 Overview

  2.2 Drug Profiles in Clinical Phase



3. Clinical Phase for Orphan Designated Cancer Drug: Phase-I

  3.1 Overview

  3.2 Drug Profiles in Clinical Phase



4. Clinical Phase for Orphan Designated Cancer Drug: Phase-I/II

  4.1 Overview

  4.2 Drug Profiles in Clinical Phase



5. Clinical Phase for Orphan Designated Cancer Drug: Phase-II

  5.1 Overview

  5.2 Drug Profiles in Clinical Phase



6. Clinical Phase for Orphan Designated Cancer Drug: Phase-II/III

  6.1 Overview

  6.2 Drug Profiles in Clinical Phase



7. Clinical Phase for Orphan Designated Cancer Drug: Phase-III

  7.1 Overview

  7.2 Drug Profiles in Clinical Phase



8. Clinical Phase for Orphan Designated Cancer Drug: Preregistration

  8.1 Overview

  8.2 Drug Profiles in Clinical Phase



9. Clinical Phase for Orphan Designated Cancer Drug: Registered

  9.1 Overview

  9.2 Drug Profiles in Clinical Phase



10. Orphan Designated Cancer Drug Available in Market

  10.1 Overview

  10.2 Marketed Drug Profiles


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name